000165349 001__ 165349
000165349 005__ 20260107201858.0
000165349 0247_ $$2doi$$a10.1093/europace/euz027
000165349 0248_ $$2sideral$$a146827
000165349 037__ $$aART-2019-146827
000165349 041__ $$aeng
000165349 100__ $$aBerruezo A
000165349 245__ $$aMortality and morbidity reduction after frequent premature ventricular complexes ablation in patients with left ventricular systolic dysfunction.
000165349 260__ $$c2019
000165349 5060_ $$aAccess copy available to the general public$$fUnrestricted
000165349 5203_ $$aAims
Ablation of frequent premature ventricular complexes (PVCs) improves left ventricular ejection fraction in patients with left ventricular (LV) systolic dysfunction. This study aims to evaluate the long-term hard outcomes and potential prognostic variables in this population.
Methods and results
Prospective multicentre study including 101 consecutive patients [56 ± 12 years old, 62 (61%) men] with LV systolic dysfunction and frequent PVCs who underwent PVC ablation before November 2015. The last evaluation performed was considered the long-term follow-up (LTFUP) evaluation. Mean follow-up was 34 ± 16 months (range 24–84 months). Ablation was successful in 95 (94%) patients. There was a significant reduction in the PVC burden from 21 ± 12% at baseline to 3.8 ± 6% at LTFUP, P < 0.001. Left ventricular ejection fraction improved from 32 ± 8% at baseline to 39 ± 12% at LTFUP (P < 0.001) and New York Heart Association class from 2.2 ± 0.6% to 1.3 ± 0.6% (P < 0.001). Brain natriuretic peptide levels decreased from 136 (78–321) to 68 (32–144) pg/mL (P = 0.007). Most of this improvement occurs during the first 6 months after ablation. Persistent abolition of at least 18 points of the baseline PVC burden was independently and inversely associated with the composite endpoint of cardiac mortality, cardiac transplantation, or hospitalization for heart failure during follow-up [hazard ratio 0.18 (0.05–0.66), P = 0.01].
Conclusion
In patients with LV systolic dysfunction, ablation of frequent PVCs induces a significant improvement in functional, structural, and neurohormonal status, which persists at LTFUP. A sustained reduction in the baseline PVC burden is associated with a lower risk of cardiac mortality, cardiac transplantation, or hospitalization for heart failure during follow-up.
000165349 540__ $$9info:eu-repo/semantics/openAccess$$aAll rights reserved$$uhttp://www.europeana.eu/rights/rr-f/
000165349 590__ $$a4.045$$b2019
000165349 591__ $$aCARDIAC & CARDIOVASCULAR SYSTEMS$$b40 / 138 = 0.29$$c2019$$dQ2$$eT1
000165349 592__ $$a2.053$$b2019
000165349 593__ $$aPhysiology (medical)$$c2019$$dQ1
000165349 593__ $$aCardiology and Cardiovascular Medicine$$c2019$$dQ1
000165349 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000165349 700__ $$aPenela D
000165349 700__ $$0(orcid)0000-0001-9187-1773$$aJáuregui B
000165349 700__ $$aSoto-Iglesias D
000165349 700__ $$aAguinaga L
000165349 700__ $$aOrdóñez A
000165349 700__ $$aFernández-Armenta J
000165349 700__ $$aMartínez M
000165349 700__ $$aTercedor L
000165349 700__ $$aBisbal F
000165349 700__ $$aAcosta J
000165349 700__ $$aMartí-Almor J
000165349 700__ $$aAceña M
000165349 700__ $$aAnguera I
000165349 700__ $$aRossi L
000165349 700__ $$aLinhart M
000165349 700__ $$aBorràs R
000165349 700__ $$aDoltra A
000165349 700__ $$aSánchez P
000165349 700__ $$aOrtiz-Pérez JT
000165349 700__ $$aPerea RJ
000165349 700__ $$aPrat-González S
000165349 700__ $$aTeres C
000165349 700__ $$aBosch X
000165349 773__ $$g21, 7 (2019), 1079 - 1087$$pEuropace$$tEuropace$$x1099-5129
000165349 8564_ $$s396972$$uhttps://zaguan.unizar.es/record/165349/files/texto_completo.pdf$$yVersión publicada
000165349 8564_ $$s2547233$$uhttps://zaguan.unizar.es/record/165349/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000165349 909CO $$ooai:zaguan.unizar.es:165349$$particulos$$pdriver
000165349 951__ $$a2026-01-07-18:52:55
000165349 980__ $$aARTICLE